Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer

Lim, Sung Hee; Hong, Mineui; Ahn, Sung Woo; Choi, Yoon La; Kim, K.-M.; Oh, Dongryul; Ahn, Yong Chan; Jung, Sin Ho; Ahn, Myung‐Ju; Park, K.; Zo, Jae Ill; Shim, Young Mog; Sun, Jong‐Mu

doi:10.1016/j.ejca.2015.09.019

Cited by 117 publications

(109 citation statements)

References 23 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…analyzed nearly 1,500 CRC samples, showing more than 30 % PD-L1 expression in untreated tumor tissue [29]. In contrast to other cancer types [21, 22], limited data are published on PD-L1 expression in RC and a potential impact of neoadjuvant therapy on PD-L1 expression. Therefore, the aim of this study was to investigate the expression of PD-L1 in a cohort of 29 neoadjuvant treated-patients suffering from locally advanced CRC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Programmed death-ligand 1 expression in rectal cancer

et al. 2016

View full text Add to dashboard Cite

SummaryBackgroundColorectal cancer (CRC) is the fourth most common cause of death worldwide. Approximately 30 % of all CRC occurs in the rectum. Improvements in survival rates were achieved thanks to multimodal therapy, combining surgery and chemoradiation. Nevertheless, the prognosis of patients suffering from rectal cancer (RC) remains poor. Programmed cell death protein 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1) regulate tumor immune response. The aim of this study was to analyze the expression of PD-L1 in RC pre- and post-neoadjuvant therapy and evaluate PD-L1 as a biomarker and potential target for therapy.MethodsIn all, 29 patients with RC treated at the Medical University Vienna who received preoperative chemoradiation were retrospectively enrolled in this study. Expression of PD-L1 was investigated by immunohistochemistry with two different anti-PD-L1 antibodies.ResultsNo PD-L1 expression on cancer cells could be observed in all 29 cases in the specimens before chemoradiation as well as in the surgical specimens after neoadjuvant therapy. In one of the two staining methods performed, five (17.24 %) post-chemoradiation cases showed faint lymphohistiocytic staining.ConclusionNo expression of PD-L1 in RC cells before and after chemoradiation was found in our collective of 29 patients. Further investigations to evaluate the role of PD-L1 as a potential therapeutic target in RC are urgently needed.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Recently, a difference in expression of PD-L1 in post-neoadjuvant therapy tumor tissue compared with pre-neoadjuvant therapy tumor tissue was found for various cancers [21–23]. To date, the expression of PD-L1 in neoadjuvant-treated RC has not been investigated intensively.…”

Section: Introductionmentioning

confidence: 99%

Programmed death-ligand 1 expression in rectal cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Most of preclinical and clinical studies used anti-CTLA-4 mAb, especially ipilimumab, being developed earlier than other agents. Tumor tissue studies in patients receiving neoadjuvant chemo-radiotherapy reported that PD-L1 expression was increased in tumor cells, but its influence on prognosis is very conflicting [49,50]. Lastly, optimal combination schedule of RT and checkpoint blockades also has to be clarified, including fractionation schedule and sequence of RT and checkpoint blockades.…”

Section: Ongoing Trials and Future Perspectivesmentioning

confidence: 99%

Radiotherapy and immune checkpoint blockades: a snapshot in 2016

Koo

Kim

2016

Radiat Oncol J

View full text Add to dashboard Cite

Immune checkpoint blockades including monoclonal antibodies (mAbs) of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) have been emerged as a promising anticancer therapy. Several immune checkpoint blockades have been approved by US Food and Drug Administration (FDA), and have shown notable success in clinical trials for patients with advanced melanoma and non-small cell lung cancer. Radiotherapy is a promising combination partner of immune checkpoint blockades due to its potent pro-immune effect. This review will cover the current issue and the future perspectives for combined with radiotherapy and immune checkpoint blockades based upon the available preclinical and clinical data.

show abstract

“…Moreover, programmed deathligand 1 (PD-L1) expression has been reported in up to 40% of ESCC, although its prognostic role remains controversial [10]. Indeed, the expression of PD-L1 increases after conventional neoadjuvant chemoradiotherapy [11]. Since PD-L1 expression is known to be induced by activated T cells, agents targeting PD-L1 are thought to be effective in PD-L1 positive ESCC patients [12].…”

Section: Immunotherapy In Esccmentioning

confidence: 99%

Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies

2018

View full text Add to dashboard Cite

The majority of patients with esophageal cancer present with advanced disease and chemotherapy is the mainstay of palliation. However, efficacy is limited by the development of chemotherapy resistance and treatment options beyond first- and second-line treatment are scarce. Immunotherapy is a novel treatment option that has shown encouraging efficacy in several types of cancer, also in esophageal cancer. In esophageal squamous cell cancer (ESCC), early phase evaluation of immune checkpoint inhibitors has yielded promising results, however, results from phase 3 trials are currently still lacking. Besides checkpoint inhibitors, other immunogenic approaches e.g. peptide vaccines, adoptive T-cell therapy and oncolytic viruses are under development. This review describes the biological rational for immunotherapy and provides first accumulating data on its use in advanced esophageal cancer, with a focus on ESCC.

show abstract

Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer

Cited by 117 publications

References 23 publications

Programmed death-ligand 1 expression in rectal cancer

Programmed death-ligand 1 expression in rectal cancer

Radiotherapy and immune checkpoint blockades: a snapshot in 2016

Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies

Contact Info

Product

Resources

About